Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Sponsor
GlaxoSmithKline
Study ID
NCT06160609
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Belantamab Mafodotin — DRUG
    Belantamab Mafodotin will be administered.
  • GSK3174998 — DRUG
    GSK3174998 will be administered.

Study Details

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination treatment to explore in the cohort expansion phase. This study is the sub study of the Master protocol (NCT04126200).

Key Dates

Start date
Oct 7, 2019
Status verified
Feb 2024
Primary completion
Jan 9, 2023
Completion
Jan 9, 2023

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Belantamab mafodotin + GSK3174998

Primary Outcome Measure

DE Phase: Number of Participants With Dose Limiting Toxicities (DLT) [ Time Frame: Up to 21 days ]

Related Studies